Puma Biotechnology (NASDAQ:PBYI) Vs. AADI, TSVT, BDSI, DYN, VRNA, SPRO, MRNS, XLO, OMER, and THRX
Should you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Aadi Bioscience (AADI), 2seventy bio (TSVT), BioDelivery Sciences International (BDSI), Dyne Therapeutics (DYN), Verona Pharma (VRNA), Spero Therapeutics (SPRO), Marinus Pharmaceuticals (MRNS), Xilio Therapeutics (XLO), Omeros (OMER), and Theseus Pharmaceuticals (THRX). These companies are all part of the "pharmaceutical preparations" industry.
Puma Biotechnology vs.
2seventy bio (NASDAQ:TSVT) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.
Puma Biotechnology has a consensus price target of $10.00, suggesting a potential upside of 338.60%. Given Puma Biotechnology's higher probable upside, analysts plainly believe Puma Biotechnology is more favorable than 2seventy bio.
In the previous week, 2seventy bio's average media sentiment score of 0.00 equaled Puma Biotechnology's average media sentiment score.
2seventy bio has a net margin of 0.00% compared to Puma Biotechnology's net margin of -19.29%. 2seventy bio's return on equity of 0.00% beat Puma Biotechnology's return on equity.
85.4% of Puma Biotechnology shares are owned by institutional investors. 19.5% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Puma Biotechnology received 509 more outperform votes than 2seventy bio when rated by MarketBeat users. However, 100.00% of users gave 2seventy bio an outperform vote while only 66.49% of users gave Puma Biotechnology an outperform vote.
2seventy bio has higher earnings, but lower revenue than Puma Biotechnology.
Summary
2seventy bio beats Puma Biotechnology on 6 of the 11 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Puma Biotechnology (NASDAQ:PBYI) vs. Its Competitors
Puma Biotechnology Competitors List
